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Abstract
Background: Hypoxia in tumor niche is one of important factors to start regeneration of blood vessels, leading to
increase survival, proliferation, and invasion in cancer cells. Under hypoxia microenvironment, furthermore, steadily
increased hypoxia-inducible factor-1α (HIF-1α) is observed, and can increase vascular endothelial growth factor
(VEGF) expression and promote angiogenesis. Zinc protoporphyrin (ZnPP), a heme oxygenase-1 (HO-1) inhibitor, is
potential to inhibit tumor proliferation and progression. However, the mechanism of ZnPP in inhibition of tumor is
not completely clear. We hypothesize that ZnPP may modulate HIF-1α through inhibiting HO-1, and then inhibit
angiogenesis and tumor progression. This study aimed to dissect the mechanism of ZnPP in tumor suppression.
Results: We observed the amount of VEGF was increased in the sera of the colorectal cancer (CRC) patients
(n = 34, p < 0.05). Furthermore, increased VEGF expression was also measured in colorectal cancer cells, HCT-15,
culturing under mimicking hypoxic condition. It suggested that hypoxia induced VEGF production from cancer
cells. VEGF production was significantly reduced from HCT-15 cells after exposure to HIF-1α inhibitor KC7F2, suggesting
that HIF-1α regulated VEGF production. Moreover, we observed that the HO-1inhibitor ZnPP inhibited the expressions
of HIF-1α and VEGF coupled with cell proliferations of HCT-15 cells, suggesting that ZnPP blocked HIF-1α expression,
and then inhibited the consequent VEGF production. In the xenograft model, we also observed that the animals
exposed to ZnPP displayed much smaller tumor nodules and less degree of angiogenesis with decreased expression of
the angiogenesis marker, αvβ3 integrin, compared to that in normal control.
Conclusions: This study demonstrated that VEGF level in serum was elevated in the patients with CRC. The HO-1
inhibitor, ZnPP, possessed the properties of anti-tumor agent by decreasing HIF-1α levels, blocking VEGF production,
impairing tumor angiogenesis, and inhibiting tumor growth.
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Background
In the process of tumor progression, the content of oxygen
in blood is one of important factors contributes to prolifer-
ations, angiogenesis and metastasis in solid tumors. Due to
highly accelerated cell divisions and proliferations, tumor
cells survive in the microenvironments with deprived oxy-
gen termed as hypoxia, in which may elicit signals to form
new blood vessels around tumors for providing additional
oxygen and nutrient to tumors [1]. Under this hypoxia
condition, deprivation of oxygen in blood causes patho-
physiologic consequences within tumor cells, leading to ex-
acerbate tumor progression, tumor invasion and gain the
resistance to apoptotic cell death program [2, 3]. In addition
to increased capability in progression, invasion, and prolif-
eration, hypoxia may also strength tumor cells with higher
resistance to radiotherapy and chemotherapy [4, 5].
Hypoxia-inducible factor-1α (HIF-1α), a regulatory
transcription factor, plays a crucial role for tumor cells
in responding to lower oxygen in their resident micro-
environment. Increased HIF-1α induced by hypoxia
can commit the adaptive changes in gene expressions
of tumor cells [2, 6, 7]. It suggests that HIF-1α is one
of potential therapeutic targets in tumors.
Currently, zinc protoporphyrin (ZnPP), a heme oxygenase-
1 (HO-1) inhibitor, is one of therapeutic candidates of
tumors [8, 9]. It has been documented that the amount
of HO-1 is elevated under hypoxic condition, and this phe-
nomena is mediated by HIF-1α [10–12]. The physiological
function of HO-1 is to cleave heme and give products such
as carbon monoxide (CO), iron ion, and biliverdin [12].
CO and bilirubin derived from biliverdin are antioxidants
which may benefit cells in growing and surviving. It implies
that HO-1 is a cytoprotective enzyme [13–16]. In addition,
other studies also indicate that HO-1 can trigger and
regulate HIF-1α expression in hypoxic tumor cells [17].
The overexpressed HO-1 seems to link with increased
tumor growth and drug resistance to chemotherapeutic
agents [3, 18].
Since HO-1 is associated with tumor progression, it may
be as another therapeutic target in treatment of cancers
[12, 19] such as colorectal cancer (CRC) [20]. Previous
studies have indicated that the drugs by inhibition of HO-1
are considered to be potential therapeutic candidates in
the treatment of cancers [21, 22]. ZnPP is well known as
an inhibitor of HO-1 and can reduces cancer cell growth.
However, this ZnPP-induced inhibitory effect on cancer
cell growth is suggested as HO-1 independent manner by
Wong et al. [23]. This result suggests that ZnPP may be
through other unknown mechanism to inhibit tumor
growth other than the known mechanism by inhibition in
HO-1 activity. In addition to be an inhibitor of HO-1,
ZnPP also acts as an enzymatic substrate of HO-1. Due to
the similarity in structure between ZnPP and heme, ZnPP
can compete with heme to HO-1, leading to reduce the
productive levels of CO and bilirubin [24], which may
interfere, disrupt, or detour other cellular signaling path-
ways to suppress the growth of tumors [23]. However, the
detail anti-tumor mechanism of ZnPP for the CRC therapy
is still unclear and need to be evaluated. Therefore, this
presented study was to investigate the anti-tumor functions
and molecular/cellular mechanisms of ZnPP in CRC.
It has been demonstrated that tumor hypoxia induces
HO-1 expression [10], and also increases the production
of vascular endothelial growth factor (VEGF) [6, 25–27].
VEGF is a ligand of VEGF receptor expressed on the
endothelial cells, which triggers the signaling for angio-
genesis. Since HO-1 may be associated with the expres-
sion of HIF-1α and VEGF [28], we hypothesized that
HO-1 inhibitor ZnPP was able to obstruct tumor growth
and spread of cancer cells by inhibiting the HO-1-induced
HIF-1α expression coupled with VEGF-mediated angio-
genesis. In order to evaluate this hypothesis, we treated
human colorectal carcinoma cells (HCT-15) with ZnPP,
and then measured the amount of HO-1, HIF-1α and
VEGF expression level. Furthermore, we also evaluated
the therapeutic benefits in HCT-15-induced tumor xeno-
grafts after treatment of ZnPP such as in the size/volume
of tumors and the degree of angiogenesis.
Methods
Sera and tissues from the patients with colorectal cancer
The clinical samples including sera and tissues were
collected from Cheng Hsin General Hospital, Taiwan,
which was approved by the Institutional Review Board
(CHGH-IRB-(240) 100–01). The pairs of tissues including
tumors (T) and adjacent non-tumors (NT) from the CRC
patients were acquired by surgery. We only collected and
analyzed the type of colorectal adenocarcinoma. Total 34
pairs of clinical tissues from the enrolled patients were
stained using methylene blue staining and distinguished
by a pathologist. Tumor histopathology and severity were
determined according to the rules of American Joint
Commission on Cancer Staging (AJCCS) system. The 15
healthy volunteers enrolled in this study had no evidence
of known CRC. Surgery for identifying normal pheno-
type was not performed in the healthy volunteers due
to ethical issues.
HCT-15 culture and tumor xenograft model
Human colorectal carcinoma cells (HCT-15) were cultured
in F12K medium with 10 % of fetal bovine serum. All cells
were incubated at 37 °C and 5 % CO2. Male nude mice
were purchased from BioLASCO Taiwan Co., Ltd, Taiwan.
The 5-week-old mice were housed in a 12 h light cycle at
22 °C. The animal studies were approved by the institutive
ethical review committee in Institute of Nuclear Energy
Research, which followed the NIH guidelines on the care
and welfare of laboratory animals. HCT-15 cells (2 × 106)
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were subcutaneously (s.c.) inoculated into the right leg of
nude mice. Tumors were established for 10 days before the
tumor treatment and imaging.
Tumor hypoxia
For control group, HCT-15 cells were cultured in the
normal condition at 37 °C and 5 % CO2. To mimic a
hypoxic condition, HCT-15 was incubated at 37 °C with
21 % CO2 in an anaerobic incubator (Mitsubishi Gas
Chemical, Tokyo, Japan). HCT-15 cells were harvested
for detecting the carbonic anhydrase 9 (CA9), HO-1,
and β-actin expressions using Western blots when HCT-
15 cells were incubated in 24 h and 48 h.
Tumor inhibition in vitro
HCT-15 cells with 50 % confluence were cultured in
F12K medium with 2.5 μM or 10 μM of hemin and
ZnPP for 24 h. The tumor cells without treatment were
used as the experimental controls. The cell numbers were
calculated using an automatic cell counter (Invitrogen,
Massachusetts, USA). Moreover, the cells treated with or
without 10 μM of hemin and ZnPP were collected and
analyzed (n = 3) using Western blots for detecting HIF-1α,
HO-1, glucose regulated protein 78 (GRP78), and β-actin.
Apoptosis was evaluated by Annexin V-FITC staining.
The cells were washed and harvested for flow cytometric
analysis in a FACSCalibur Flow Cytometer (BD Biosciences,
New Jersey, USA).
VEGF measurement
VEGF levels were measured using a VEGF enzyme-
linked immunosorbent assay (ELISA) kit (Invitrogen,
Massachusetts, USA). There were three conditions where
the mediums were collected and measured. The mediums
were collected where (1) HCT-15 cells with 90 % conflu-
ence were cultured in normoxia or hypoxia condition, (2)
HCT-15 cells with 90 % confluence were treated with
2.5 μM or 10 μM of hemin and ZnPP, and cultured in nor-
moxia condition for 24 h, and (3) HCT-15 cells with 90 %
confluence were treated with 2.5 μM or 10 μM of hemin
and ZnPP, and cultured in hypoxia condition for 24 h.
VEGF measurements were performed according to the
manufacturer’s instructions and quality control was
ensured.
Western blots
Cells were lysed in the buffer containing 150 mM NaCl,
1 % NP-40, 0.1 % SDS, and 50 mM Tris–HCl (pH8.0).
The protein samples were mixed with two-fold sample
buffer (75 mM of Tris–HCl, pH 6.8, 10 % (v/v) glycerol,
2 % SDS (w/v), 0.002 % (w/v) bromophenol blue). Total
20 μg of each sample was analyzed in 10 % sodium dodecyl
sulfate polyacrylamide gel electrophoresis, and then trans-
ferred onto the Immobilon P membranes (Merck Millipore,
Massachusetts, USA). These PVDF membranes were
blocked in 3 % skim milk for 1 h at room temperature.
PVDF membranes were then incubated with primary
antibodies (1 μg/ml) overnight at 4 °C, and washed
using Tris buffered saline with 0.1 % tween-20. After
washing, PVDF membranes were incubated with horse-
radish peroxidase-conjugated secondary antibody (1 μg/ml)
for 2 h at room temperature. The immunoreactive proteins
were detected using ECL (enhanced chemiluminescence,
Bio-Rad, California, USA) coupling with a LAS-4000 mini
device (Fujifilm, Tokyo, Japan).
Angiogenesis imaging in vivo
The PBS (n = 3) or 100 μg of ZnPP (n = 3) were
injected into HCT-15 tumor xenografts from tail vein.
After 24 h circulation, the angiogenesis detecting agent
labeled with the near-infrared fluorescence (AngioSense
680 EX, PerkinElmer, Massachusetts, USA) was intraven-
ously injected into tail vein of HCT-15 xenograft model.
Then, the in vivo imaging system (IVIS, PerkinElmer,
Massachusetts, USA) was performed to capture the fluor-
escent images for detecting angiogenesis distribution.
Inhibition of tumor growth by ZnPP in vivo
For testing the anti-tumor effects of ZnPP, the mice were
randomly divided to three groups: PBS as control (n = 3),
10 μg of ZnPP (n = 3), and 100 μg of ZnPP (n = 3). The
mice were treated in day 11, 13, and 16 after tumor im-
plantation. The tumor sizes were measured using a digital
caliper and recorded in day 11, 13, 16, 18, and 20. Tumor
volumes were recorded and calculated using the formula:
0.52 x width2 x length, herein the width represents the
smaller tumor diameter. The mice were sacrificed in day
20, and tumors were analyzed using Western blots for de-
tecting αvβ3 integrin and β-actin.
Statistical analysis
The bands in Western blots were quantified by densito-
metric analysis using Multi Gauge v3.2 software (Fujifilm,
Tokyo, Japan). Statistical analysis was performed using
GraphPad Prism V5.01 software (GraphPad Software, Inc.,
California, USA). All analysis data with more than two
groups were performed by ANOVA followed by post-hoc
analysis using Bonferroni’s test. Student’s t test was used
to compare two groups. The analysis of receiver operating
characteristic curve was performed to clarify the cut-off
value using SPSS software. Data were presented as
mean ± SD. The significance difference (p value) was
acceptable as p < 0.05.
Results
VEGF elevated in the sera of CRC patients
To compare VEGF levels in sera between the CRC pa-
tients and the normal individuals, sera samples were
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acquired and measured using the ELISA assay. Thirty-
four CRC patients and 15 healthy volunteers were en-
rolled and participated in this study. The tumor tissues
were first collected by surgical operation and then stained
using methylene blue dye for distinguishing tumors from
the adjacent non-tumor tissues in each clinical biopsy
specimens (Fig. 1a). Due to the medical ethics, the normal
tissues from the healthy volunteers were not collected. The
serological VEGF levels in CRC group were 222 ± 38 pg/ml
compared to that in healthy group measured as 105 ±
31 pg/ml (Fig. 1b), indicating the significantly increased
VEGF expression in sera of CRC patients. Moreover, the
sensitivity and specificity of VEGF were 0.618 and 0.667,
respectively, with a cut-off value of 122.5 pg/ml according
to the analysis of receiver operating characteristic curve.
Tumor hypoxia promoted cell growth and enhanced
HO-1 and VEGF expression in HCT-15 cells
To elevate the role of hypoxia on cell survival, HCT-15
cells were cultured on hypoxic incubator supplemented
with 21 % CO2 as described in the section of Methods
and Materials. HCT-15 cells growing under hypoxic con-
dition displayed significantly higher amount of carbonic
anhydrase-9 (CA9), a hypoxic marker, compared to cells
growing under normoxia condition (Fig. 2a). Further-
more, HCT-15 cells culturing in hypoxic condition
gained more than 50 % in cell viability compared to
normoxia (Fig. 2b). Since HIF-1α was more stable with
longer half-life in activity under hypoxia, leading to
promote tumor angiogenesis [6, 29], we further mea-
sured the expressions of HO-1 and VEGF in HCT-15
cells culturing in hypoxic condition. To measure the
changes of HO-1 levels expressed from HCT-15 grow-
ing under normoxia and hypoxia, cell protein lysates
were acquired and then detected using Western blots.
The detection of VEGF secreted from HCT-15 into cul-
tured medium was measured using ELISA. We found
that HO-1 expression was significantly increased in HCT-
15 cells cultured either for 24 h or 48 h in hypoxic condi-
tion (Fig. 2c). Moreover, the amounts of VEGF in cell
supernatant derived from cells culturing under hypoxia
and normoxia were measured and the results revealed
more than 3-fold increase in VEGF production from cells
grew under hypoxic condition (Fig. 2d). Moreover, the
hypoxia-induced VEGF production from HCT-15 cells
was blocked by KC7F2, a HIF-1α inhibitor. These results
suggested that HIF-1αplayed an important role on regula-
tion to induced HO-1 and VEGF expressions.
ZnPP inhibited tumor proliferation coupling with reduced
HIF-1α and HO-1 expressions
Since hypoxia-induced HO-1 was observed in tumor cells,
we hypothesized that HO-1 may act as a therapeutic target
for treatment of cancers. ZnPP is a competitive HO-1 in-
hibitor for competing with heme. Therefore, we investi-
gated the inhibitory roles of ZnPP on survival of HCT-15
Fig. 1 VEGF overexpressed in the sera of the enrolled patients with colorectal cancer. a Total 34 pairs of clinical tissues from the enrolled patients
were stained using methylene blue staining and distinguished by a pathologist. The healthy volunteers were not tested due to ethical issues,
who had no evidence of known CRC. NT: non-tumor; T: tumor. Scale bar: 100 μm. b VEGF levels were increased in the sera of patients with
colorectal cancer (n = 34) compared to that in healthy volunteers (n = 15). *p < 0.05
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cells. HTC-15 cells were cultured with medium containing
2.5 or 10 μM and the result demonstrated that numbers of
HCT-15 cells were significantly decreased with ~75 %
reduction at 10 μM of ZnPP (p < 0.05) but no cytotoxic ef-
fect at 2.5 μM. Moreover, hemin, a HO-1 inducer, did not
statistically alter the numbers of cells either at 2.5 or
10 μM of hemin (Fig. 3a). In order to detail the cytotoxic
mechanism of ZnPP on HCT-15 cells, we analyzed and
measured several candidate proteins in expressions level
such as HO-1, HIF-1α, and endoplasmic reticulum (ER)
stress GRP78 in HCT-15 cells cultured in medium either
containing 10 μM of hemin or 10 μM of ZnPP. The results
indicated that hemin significantly increased amounts of
HIF-1α and HO-1, although no statistically significance in
hemin-enhanced HO-1 production. In contrast to hemin,
ZnPP significantly reduced HIF-1α and HO-1 expressions
(Fig. 3b & c). Both hemin and ZnPP did not affect the ex-
pression of GRP78, an ER stress protein overexpressed
under extreme conditions countering to non-specific stim-
ulations [30]. To characterize the potential mechanism of
ZnPP-induced reduction in cell numbers, the apoptotic
analysis was performed and the results demonstrated that
ZnPP at 10 μM did not trigger apoptotic program in
HCT-15 cells (Fig. 3d). We presumed that ZnPP may re-
duce HIF-1α expression through inhibiting HO-1 activity,
and consequently inhibit tumor proliferation.
ZnPP reduced hypoxia-mediated VEGF release in HCT-15
cells in vitro
Our data demonstrated that hypoxia mediated HO-1 pro-
duction and VEGF release from HCT-15 cells, ZnPP, how-
ever, inhibited HIF-1α expression. Therefore, we were
interested in evaluating the effects of ZnPP on VEGF ex-
pression in HCT-15 cells. To collect and measure the
amounts of VEGF in supernatant of cultured medium, the
HCT-15 cells were cultured in medium containing either
with hemin or ZnPP at concentration of 2.5 or 10 μM for
24 h incubation. VEGF levels were then measured using
ELISA assay. The results showed that ZnPP at 10 μM sig-
nificantly reduced VEGF levels by 40 % (262 ± 18 pg/ml)
compared to control group without any treatments (438 ±
62 pg/ml). Meanwhile, hemin displayed no any modulat-
ing effects on VEGF production in HCT-15 cells either at
2.5 or 10 μM (Fig. 4a). This result indicated that ZnPP
specifically reduced VEGF release from HCT-15 cells.
Since tumor hypoxia specifically induced VEGF expres-
sion and release as shown in Fig. 2d, we would like to see
whether ZnPP can interfere hypoxia-induced VEGF pro-
duction or not. We cultured cells under hypoxic chamber
either with or without treatments of ZnPP and then the
measurements of VEGF were acquired and compared.
The results first confirmed that hypoxia induced VEGF
production from HCT-15 cells. Furthermore, ZnPP
Fig. 2 Tumor hypoxia elevated HO-1 and VEGF levels. a Tumor hypoxia marker, carbonic anhydrase IX (CA9), increased in the condition mimicking
hypoxia compared to normoxia. b Cell viability was increased when HCT-15 cells were cultured in hypoxic condition for 24 h compared to
nomoxia. c HO-1 overexpressed in mimic tumor hypoxia condition compared to that in normoxia detected using Western blots. d The secreted VEGF
elevated in tumor hypoxia compared to that in normoxia. In addition, a HIF-1α inhibitor, KC7F2, was used to block the HIF-1α function, leading to
decrease VEGF levels, revealing that VEGF overexpressed in tumor hypoxia, and was regulated by HIF-1α. *p < 0.05. **p < 0.01. ***p < 0.001
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inhibited hypoxia-induced VEGF production in a dose-
dependently manner (Fig 4b).
ZnPP reduced tumor angiogenesis and tumor growth in
HCT-15-induced xenografts
We demonstrated that ZnPP-mediating reduction in
HCT-15 proliferation combined with decreased VEGF
release, so we further liked to investigate the in vivo in-
hibitory potential of ZnPP on tumor and angiogenesis in
animals suffered with cancers. VEGF are positively asso-
ciated with angiogenesis during progression of cancers.
To characterize the inhibitory potential of ZnPP in angio-
genesis, ZnPP was intravenously administrated into xeno-
grafts with HCT-15 cancer cells and then angiogenesis
were detected and analyzed using an in vivo imaging
system (IVIS) coupled with a near-infrared labeled
fluorescent macromolecule (AngioSense 680 EX, Perkin
Elmer, Massachusetts, USA) via intravenous adminis-
tration. The results indicated that less fluorescence-
labeled area combined with lower fluorescent intensity
(~50 % reduction) in the animals pretreated with ZnPP
compared to that in animals only treated with PBS
(Fig. 5a and b), revealing that ZnPP reduced tumor
angiogenesis in vivo. In order to confirm the results de-
rived from imaging analysis by IVIS, we measured the
amount of αvβ3 integrin using Western blotting. Ac-
cording to the literatures, αvβ3 is one of angiogenetic
markers [31, 32]. The αvβ3 integrin expressed from
ZnPP-treated tumor tissues were significantly reduced
by 50 % compared to that in PBS treatment (Fig. 5c and d).
The decreased ratio of αvβ3 integrin was consistent
with that our previous observation in IVIS detection of
Fig. 3 ZnPP inhibited cell proliferation and decreased HIF-1α levels in HCT-15 cells. a HCT-15 cells cultured in normoxia were treated with hemin,
a HO-1 inducer, or ZnPP, a HO-1 inhibitor, using a dose-dependent manner, and the cell number was counted and compared. The cells without
treatment were used as control (Ctrl). ZnPP (10 μM) significantly inhibited the HCT-15 cell viability, but hemin did not. b & c The treated cells were
harvested and investigated (n = 3) for detecting the expressions of HO-1, HIF-1α, ER stress marker GRP78, and β-actin. Hemin increased HIF-1α and
HO-1 (without significance), but ZnPP decreased HIF-1α and HO-1. The ratio of GRP78/β-actin was equivalent among the groups as an indicator excluding
the treated effects derived from hemin or ZnPP. d Furthermore, apoptosis was not detected in HCT-15 cells treated with 10 μM of ZnPP, whereas 10 μM
of cisplatin was used as a positive control to induce apoptosis, indicating that ZnPP inhibited HCT-15 cell proliferation without leading to
apoptosis. *p < 0.05. ***p < 0.001. #p < 0.05 compared to ctrl
Cheng et al. Journal of Biomedical Science  (2016) 23:18 Page 6 of 10
tumor angiogenesis. These results indicated that ZnPP
inhibited tumor angiogenesis and this ZnPP-mediated
anti-angiogenesis effect was VEGF dependent.
Beside the role of ZnPP on anti-angiogenesis, we also
would like to evaluate the therapeutic effects of ZnPP on
HCT-15-induced xenografts. Since ZnPP was demonstrated
to reduce VEGF-triggered angiogenesis, ZnPP was injected
into HCT-15-induced xenografts through tail vein at the
day 11, 13, and 16 after tumor implantation. We found that
both concentration at 10 μg and 100 μg of ZnPP signifi-
cantly reduced the tumor size compared to PBS group
(Fig. 6a and b). The results indicated that ZnPP may be
a potential therapeutic candidate for patients with colo-
rectal cancer.
Discussion
ZnPP, one of metalloporphyrins, is a HO-1 inhibitor by
competing metabolized heme. A previous study sug-
gests that tin protoporphyrin IX (SnPP) is the most po-
tent HO-1 inhibitor in the internal anal sphincter (IAS)
smooth muscle [33]. Literatures also have indicated that
other inhibitors but not SnPP show strong inhibitory
function on HO-1 activity in liver [33]. It suggested the
HO-1 inhibitors are belonging to tissue-specific inhibitors.
Fig. 5 ZnPP inhibited tumor angiogenesis in the HCT-15-induced tumor xenografts. a-b The mice were injected with PBS or 100 μg of ZnPP through
tail vein three times (day 11, 13, and 16), and the angiogenesis fluorescent agent was injected for measuring the angiogenesis levels within tumors.
The fluorescent intensity per square measure in the area of circle decreased by ~50 % in tumors treated with ZnPP compared to that treated with PBS.
Tumors were indicated by circles. c-d The tumors from HCT-15-induced xenografts treated with PBS or ZnPP were investigated and compared using
Western blots. The angiogenesis marker, αvβ3 integrin, decreased in the tumors treated with ZnPP compared to PBS by ~50 %. *p < 0.05
Fig. 4 ZnPP reduced tumor hypoxia-mediated VEGF release. a HCT-15 cells were treated with hemin or ZnPP cultured in normoxia, and the cultured
mediums were collected and investigated using ELISA assay. We found that ZnPP (10 μM) decreased VEGF secretion in HCT-15 cells, but hemin did
not. b HCT-15 cells was treated with ZnPP and cultured in hypoxia condition. Tumor hypoxia increased VEGF, but ZnPP reduced hypoxia-induced VEGF
levels. *p < 0.05. **p < 0.01
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Compared to other metalloporphyrins such as copper pro-
toporphyrin (CuPP), ZnPP displays more potent inhibitory
function on HO-1 activity in tumor [34], indicating that
ZnPP may be a good candidate to inhibit growth and
progression of tumors. A particular study indicates that
ZnPP suppresses cyclin D1 gene expression in cancer cells
is HO-1 independent, but SnPP does not [35]. Another
study demonstrated that ZnPP-induced tumor suppres-
sion effect is a HO-1-independent manner, but via in inhi-
biting the Wnt/β-catenin signaling pathway in cancer cells
[36]. Thus, it is likely that ZnPP, a HO-1 inhibitor, not
only reduces the HO-1 activity, but also triggers other
inhibitory effects on other mechanism associated with
tumor cell progression.
In our current study, we found that ZnPP prohibited
cell proliferation in HCT-15 cells, decreased HIF-1α and
HO-1 levels, reduced VEGF release, and inhibited angio-
genesis. Tumor hypoxia prolongs HIF-1α activity, and
induces VEGF expression, leading to promote angiogenesis
and malignant tumor growth. In this study, we demon-
strated that KC7F2, a HIF-1α inhibitor, inhibited HIF-1α-
mediated VEGF production. Furthermore, HO-1 directly
regulated HIF-1α production [17]. Therefore, HO-1 inhibi-
tor such as ZnPP was demonstrated with capability in
reduction of HIF-1α expression and VEGF levels in this
study. We speculated that tumor inhibitory effect of ZnPP
was partially due to decreasing HIF-1α expression through
reducing HO-1 activity, and then consequently decreased
tumor angiogenesis.
Tumor hypoxia often derived from tumor-lodging micro-
environment in many solid tumors which receive limited
amounts of oxygen supply promptly promotes the forma-
tion of new blood vessels. The advanced tumors exhibit
large volume coupled with higher degree in angiogenesis
[37]. In order to determine the inhibitory effects of ZnPP to
angiogenesis, we selected adequate tumor size near to
100 mm3 for imaging angiogenesis after administration of
ZnPP, in which was sufficient area for observing fluorescent
signals on the location of implanted tumors. Besides, since
the in vivo near-infrared AngioSense 680 EX fluorescent
agent is a PEGylated large scaffold (250 kDa) belonging to a
non-targeted tumor vascular fluorescent agents [38, 39], we
utilized this agent to detect tumor angiogenesis. The
results demonstrated that ZnPP significantly reduced
the degree of tumor angiogenesis in the HCT-15-induced
tumor xenografts.
It has been well known that hypoxia-induced HIF-1α
mediates the down-stream signaling pathways for various
forms of genes for response to tumor progression and in-
vasion. Since elevated HIF-1α participates in tumor pro-
gression, HIF-1α is considered as one of tumor markers
and can be useful as a targeted candidate for anti-tumor
therapeutics. The therapeutic approaches by targeting to
HIF-1α may impact several fields, including (a) reduction
of HIF-1α synthesis, (b) accelerating degradation of HIF-
1α, and (c) inhibiting the transactivation of the HIF-1α-
mediated down-stream signaling events. In contrast to
HO-1 inducer hemin increased HIF-1α levels, this study
demonstrated that HO-1 inhibitor ZnPP reduced HIF-1α
expression, indicating that HO-1 may regulate amounts of
HIF-1α, and can be qualified as a targeted protein for de-
veloping anti-tumor therapeutics.
A previous study has reported that both ZnPP and
hemin are an oxidative iron-binding porphyrin, inhibits
CoCl2-induced HIF-1α expression through accelerating
HIF-1α degradation [40]. However, this study revealed
the induction of HIF-1α by hemin in the normal cul-
tured condition, but only ZnPP reduced HIF-1α levels.
The difference between hemin (iron) and ZnPP (zinc) is
(a) in the function either to induce or inhibit HO-1 ac-
tivity, and (b) the various forms of metals enclosed in
the porphyrins. In addition to regulation of HO-1 activity,
zinc metal may have other effects or biological roles to
modulate the activity of HIF-1α in tumors [41, 42]. Our
results revealed that ZnPP possessed higher inhibitory
effects than hemin on HIF-1α expression and proliferation
of tumor cells, suggesting that ZnPP is a therapeutic can-
didate for treatment of cancers.
Fig. 6 ZnPP inhibited tumor growth in the HCt-15-induced tumor
xenografts as a potential therapeutic agent. a The mice were treated
with PBS, 10 μg or 100 μg of ZnPP three times (day 11, 13, and 16), and
the tumor sizes were recorded and compared. We found that 100 μg of
ZnPP significantly reduced the tumor growth, and b decreased tumor
volume by ~50 %. *p <0.05. **p <0.01
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Conclusions
In conclusion, this study demonstrated that ZnPP is not
only a HO-1 inhibitor, but also a potential anti-tumor
agent inhibiting tumor proliferation. We found that
ZnPP reduced HIF-1α expression in HCT-15 cells, and
consequently inhibited hypoxia-mediated VEGF release.
Moreover, we also demonstrated that ZnPP inhibited
HCT-15 cell proliferation, and reduced tumor growth in
the HCT-15-induced tumor xenografts as an ideal thera-
peutic agent. The angiogenesis level was decreased in the
tumor exposed to ZnPP compared to the group treated
without exposure of ZnPP. These findings may detail the
ZnPP-mediated anti-tumor mechanism. Since the results
revealed that VEGF was highly elevated in the sera of
CRC patients using an ELISA assay, we speculated and
suggested that ZnPP may be a potential therapeutic agent
against CRC.
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